The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (OCA), from Intercept Pharmaceuticals (Nasdaq: ICPT), for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis.
Given the Food and Drug Administration’s recent Complete Response Letter (CRL) stating the treatment’s current efficacy and safety data were insufficient to support accelerated approval, the cost-effectiveness watchdog announced it will no longer hold the planned August 2020 public meeting to deliberate over the findings of this report.
“Although we do not know the reasons for the FDA decision, ICER’s review of OCA concluded that the potential cardiovascular risks of therapy led to uncertainties about whether treatment would be beneficial or harmful in many patients,” said Dr David Rind, the ICER’s chief medical officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze